Harvard Bioscience (HBIO) Research & Development (2010 - 2026)
Harvard Bioscience (HBIO) posted quarterly Research & Development of $5.3 million for Q1 2026, up 7.32% year-over-year from $5.0 million in Q1 2025, and down 57.57% quarter-over-quarter from $12.6 million in Q4 2025.
Harvard Bioscience (HBIO) Research & Development (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has reported Research & Development for 17 consecutive years, with $5.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 7.32% year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $24.6 million (up 15.51% YoY), while the FY2025 annual figure was $19.2 million, down 13.49% from the prior year.
- Research & Development retreated to $5.3 million in Q1 2026 per HBIO's latest filing, from $12.6 million in the prior quarter.
- Across five years, Research & Development topped out at $15.4 million in Q4 2023 and bottomed at $2.1 million in Q3 2025.
- Historically, Research & Development has averaged $5.8 million across 5 years, with a median of $5.4 million in 2024.
- Annual changes were most pronounced in 2022 — Research & Development soared 168.88% — and 2024, when it plunged 65.07%.
- Harvard Bioscience's Research & Development stood at $5.9 million in 2022, then soared by 159.68% to $15.4 million in 2023, then slumped by 65.07% to $5.4 million in 2024, then jumped by 133.07% to $12.6 million in 2025, then slumped by 57.57% to $5.3 million in 2026.
- Business Quant data shows HBIO's Research & Development at $5.3 million in Q1 2026, $12.6 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 132.71 Bn | 127.50 Bn | 1.96 Bn | 370.60 Mn |
| 2 | Becton Dickinson | 51.57 Bn | 50.71 Bn | 2.32 Bn | 258.00 Mn |
| 3 | Alcon | 35.52 Bn | 34.17 Bn | 1.68 Bn | 663.00 Mn |
| 4 | Resmed | 33.28 Bn | 31.81 Bn | 861.22 Mn | 105.73 Mn |
| 5 | Medline | 27.86 Bn | 25.18 Bn | 2.22 Bn | - |
| 6 | West Pharmaceutical Services | 25.15 Bn | 24.71 Bn | 329.20 Mn | 19.70 Mn |
| 7 | Solventum | 15.31 Bn | 14.91 Bn | 1.29 Bn | 178.00 Mn |
| 8 | Cooper Companies | 14.86 Bn | 14.72 Bn | 735.40 Mn | 42.50 Mn |
| 9 | Baxter International | 13.63 Bn | 11.48 Bn | 1.03 Bn | 129.00 Mn |
| 10 | Harvard Bioscience | 34.12 Mn | 27.61 Mn | 12.63 Mn | 5.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.40 Mn |
| Mar 31, 2026 | 5.34 Mn |
| Dec 31, 2025 | 12.57 Mn |
| Sep 30, 2025 | 2.13 Mn |
| Jun 30, 2025 | 4.54 Mn |
| Mar 31, 2025 | 4.97 Mn |
| Dec 31, 2024 | 5.40 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Jun 30, 2024 | 5.40 Mn |
| Mar 31, 2024 | 5.90 Mn |
| Dec 31, 2023 | 15.45 Mn |
| Sep 30, 2023 | 2.76 Mn |
| Jun 30, 2023 | 2.96 Mn |
| Mar 31, 2023 | 5.98 Mn |
| Dec 31, 2022 | 5.95 Mn |
| Sep 30, 2022 | 2.76 Mn |
| Jun 30, 2022 | 3.50 Mn |
| Mar 31, 2022 | 6.69 Mn |
| Dec 31, 2021 | 16.79 Mn |
| Sep 30, 2021 | 2.66 Mn |